Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
Its that time of year again! Jade Teakell is leading team #UrineItToWinIt for #HCWvsHunger 2024. Read more.
2023 brought us has dogma shredding data on hyponatremia and the importance of different diuretics. It has new therapies for old diseases like IgA and hypertension. New drugs for new diseases like inaxaplin for AMKD. And it has new data on old debates like what IVF is best and do thiazides really prevent kidney stones. It is a great list. Dig in!
Yet another new medication class for use in the RAAS cascade. BI 690517, an aldosterone synthase inhibitor, has been shown to significantly reduce proteinuria with or without empagliflozin. VA by Brian Rifkin.
Does the cessation of RAS inhibitors prior to surgery contribute to reduced myocardial injury? Check out the SPACE TRIAL visual abstract by NSMC intern Ali Rizvi
A very colourful visual abstract from Sabarinath!
Checkout the role of Sparsentan in FSGS - The Duplex Trial VA by NSMC Intern Pallavi Prasad
Fascinating observational study on hyponatraemia correction rates this week, catch-up here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) November 17, 2023
✳️10 tweet #NephJC catch-up ✳️
The challenge has been declared to the concept that rate of hyponatraemia correction is as vital as nephrologists have been telling you - to know if you agree, you need to know the studies the challenge is based upon🧵👇 pic.twitter.com/S5XVH9QqRb
Another sterlling visual abstract from Milagros Flores
This week, nephrologists hope they found the key to no-dialysis-land, where kindness and detailed, multistep interventions make the path to kidney transplant much easier. This was foreseen in our Freely Filtered episode and disputed during #KidneyWK 2023 late-breaking clinical trials session. Still, when it comes to RCTs’ results, will it be Deja Vu or a happy ending?
Check out the beautiful Visual Abstract for this week’s NephJC by Arjun Mohan.
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
TenTweetNephJC on X. Natriuresis guidance for intensification of diuretics is one strategy to PUSH decongestion in patient’s with acute heart failure.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) October 5, 2023
Adequate decongestion to prevent rehospitalization & excess mortality are the goals when treating HF. So, why do we fail so often?
This week we look at natriuresis guided diuretic therapy in hospitalized HF patients.
✳️10 tweets #NephJC catch-up ✳️ pic.twitter.com/PjDKcscTOV
Does natriuresis-guided diuretic therapy in patients with acute heart failure improve clinical outcomes?
NSMC Intern Sameen Aamer answers it with a VA
